|Bid||10.40 x 900|
|Ask||10.90 x 800|
|Day's Range||10.36 - 11.18|
|52 Week Range||1.10 - 30.99|
|Beta (5Y Monthly)||-1.77|
|PE Ratio (TTM)||9.39|
|Earnings Date||Nov 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.00|
It's hard to think of an industry that was more impacted by the 2020 COVID pandemic than diagnostics. The often-overlooked part of the healthcare system sprang into action, testing more than 250 million people last year in the U.S. alone. Co-Diagnostics (NASDAQ: CODX), Aspira Women's Health (NASDAQ: AWH), Fulgent Genetics (NASDAQ: FLGT), GenMark Diagnostics (NASDAQ: GNMK), and Natera (NASDAQ: NTRA) were the five best-performing diagnostics companies last year among those with a market cap above $200 million.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel discussion on diagnostics and devices hosted by Scott Gottlieb, M.D., at the H.C. Wainwright & Co. BioConnect 2021 Conference, being held January 11-14.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial reporting for the fourth quarter 2020, unaudited quarterly revenue is anticipated to be the highest in the Company's history and to surpass analyst estimates.